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INTRODUCTION
On April 6, 1999, a meeting jointly sponsored by the
National Cancer Institute (NCI) and the National Heart ,
Lung, and Blood Institute (NHLBI) was convened at the
National Institutes of Health (NIH) to discuss clinical trials
re s e a rch in hematopoietic stem cell transplantation. The
institutes and a large proportion of the transplantation com-
munity have jointly expressed the need for new strategies
and support mechanisms to foster more rapid translation of
advances in transplantation biology emanating from basic
re s e a rch in cellular immunology, immunopharm a c o l o g y,
tumor cell biology, and molecular genetics, as well as for
clinical investigations of patients receiving allogeneic and
autologous hematopoietic stem cell transplants, into more
e ffective and consistently curative transplantation approaches
for the treatment of selected cancers and lethal disorders of
hematopoiesis and immunity. There is a general concern
that the existing infrastru c t u re for the conduct of phase II
trials evaluating new strategies for transplantation, trans-
plantation-associated tumor- t a rgeted therapies, and the
t reatment of transplant-associated complications is inade-
quate to exploit, in a timely manner, the many opportunities
suggested by current research.
In addition, several investigators have voiced their con-
cern that phase III trials conducted by existing cooperative
trial groups that compare allogeneic or autologous hemato-
poietic stem cell donor grafts with other chemoradiotherapy
regimens in the treatment of malignancies have been
plagued by slow accruals and have invoked dated transplan-
tation strategies. Furt h e rm o re, these groups have not provided
a mechanism for conducting phase III trials to examine
transplant-specific issues (eg, the type of transplant used or
the type of donor recruited).
The NCI and NHLBI have each recognized these limi-
tations and have raised the possibility of committing
re s o u rces for the development and support of altern a t i v e
o rganizational stru c t u res, or collaborative interactions,
specifically designed to foster more rapid translation of
advances in the science of hematopoietic stem cell trans-
plantation into more effective and more broadly applicable
therapeutics. In preparing to implement such an initiative,
the institutes are now engaged in intensive dialogue with the
transplantation community to identify critical needs, includ-
ing identification and prioritization of trials (developmental
phase I and II trials or validating phase III trials) to be con-
ducted and the types of organizational infrastru c t u re best
suited for their implementation. If provided with appropri-
ate support, this new initiative could expedite evaluation of
the most promising new transplantation strategies emerging
in this rapidly evolving field.
The network envisioned by the institutes to be best
suited to this mission, as articulated by Dr. R. Wittes, Direc-
tor of Cancer Therapy Evaluations Program at NCI, has
several desirable features. Ideally, it should be inclusive and
open to many ideas and to participation by a large propor-
tion of transplantation centers in this country. This network
should exploit the rich science of transplantation biology in
its development and prioritization of clinical trials to maxi-
mize chances of substantive pro g ress. It must be able to
rapidly accrue patients to prioritized trials, to permit early
identification of substantive advances, and to quicken the
pace of translation of advances in research. It was also sug-
gested that, whenever indicated, the network should take
advantage of existing national re s o u rces [eg, the Intern a-
tional Bone Marrow Transplant Registry (IBMTR)/Autolo-
gous Bone Marrow Transplant Registry (ABMTR), National
M a rrow Donor Program (NMDP), or the cooperative
groups] for data management and analysis, or for data safety
and monitoring, to avoid costly duplication of eff o rt. The
possibility of such a network developing working part n e r-
ships with pharmaceutical, biotechnologic, and health care
industries was also encouraged.
The organizational stru c t u re of such a network has not
been specified by the institutes. However, both the NCI, with
its Cooperative Groups, and the NHLBI, with its Clinical
Centers have developed functional organizational plans that
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meet the needs of multicenter groups collaborating in the
conduct of advanced phase II and phase III trials. These
cooperative groups or disease-focused clinical centers each
have a governing board or steering committee, one or more
committees charged with developing protocols for the various
underlying diseases, a separate committee for scientific re v i e w
and prioritization of trials, an independent data coord i n a t i n g
center or facility, and a review board for monitoring data
f rom participating centers, ensuring protocol compliance and
c o n firming the accuracy of data and their interpre t a t i o n .
THE TRANSPLANTATION TRIALS GROUP, A PROPOSED
MECHANISM TO EXPEDITE PHASE III TRIALS IN
HEMATOPOIETIC CELL TRANSPLANTATION
The need for new mechanisms to conduct phase III trials
of transplantation-related strategies had been raised by a
g roup of investigators participating in studies being conducted
with the IBMTR/ABMTR and the NMDP. At a pre l i m i n a ry
meeting conducted during the IBMTR/ASBMT meeting at
Keystone, Colorado, in March 1999, Drs. N. Kernan, J. A n t i n ,
D. We i s d o rf, J. Voss, M. Horowitz, and C. Howe presented a
plan for a “National Transplant Trials Gro u p . ”
The stated intent of this group would be to provide a
new cooperative group structure to conduct validating phase
III trials in the field of hematopoietic stem cell transplanta-
tion. This group was proposed to address a perceived need
for phase III trials in transplantation, deficiencies in national
randomized trials that compare transplantations with other
modalities in the treatment of specific diseases, and the diffi-
culties that almost all single centers experience in accruing
sufficient numbers of patients for such comparative trials.
The stated goal of the proposed transplantation trials
group would be to establish a democratic, inclusive organi-
zation with a minimal bureaucracy for the conduct of phase
III trials covering a broad range of transplantation-re l a t e d
issues (eg, conditioning regimens, graft manipulations, post-
transplantation immunotherapy). The group would consist
of all institutions accredited for transplantation who wish to
p a rticipate. Participation in specific trials would be volun-
Table 1. New Transplant Sources and Regimens*
Stem Cell Sources Preparatory Regimens
Donor possibilities New myeloablative drug and radiation regimens
Autologous HLA-matched relative Leukemia- or lymphoma-targeted radioimmunoconjugates and 
HLA-matched unrelated adult immunotoxins 
HLA-matched unrelated cord blood
HLA-disparate relative (1-3 HLA alleles) Nonmyeloablative drug and/or radiation regimens
HLA-homozygous stem cell pools (minitransplants)
Stem cell transplants
Unfractionated marrow
Unfractionated peripheral blood stem cells
Tumor cell–purged grafts
T-cell–depleted grafts
Isolated stem cell fractions
In vitro expanded stem cells
Genetically marked stem cells
*HLA indicates human leukocyte antigen.
Table 2. Exploitation and Control of Alloreactions Post-Transplant*
Post-Transplantation Eradication of Residual Disease and
Modulation of Allointeractions Augmentation of Tumor Resistance
Potentiation of engraftment Tumor-targeted monoclonal antibodies
Stem cell dose augmentation Adoptive cell therapies
Natural killer (NK) cell infusions Suicide vector-modified host-specific alloreactive donor T cells
Facilitator T-cell infusions Tumor-reactive donor T cells
Suicide vector-modified donor anti-host T cells Leukemic APC-selective
Selected cytokines Fusion gene-specific
Prevention of GVHD Differentiation antigen-specific
T-cell depletion systems in vitro Tumor-reactive NK cell clones
New drugs and T-cell antibodies in vivo ScFv vector-midified vectors
Cytokine antagonists Retargeted T- and NK-cell effectors
CD4, CD8 analogues ScFv vector-modified vectors
CDA 4 immunoglobulin of donor graft-specific toleration
Depletion of host APCs
*APC indicates autologous packed cells; GVHD, graft-versus-host disease; and ScFv, single-chain variable fragment.
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t a ry, but if an institution is committed to a given trial, it
would be required to commit to enter all eligible and con-
senting patients to that trial.
The gro u p ’s organization would consist of a ro t a t i n g
b o a rd of directors as the governing body, a nominating
committee to review and propose members and officers, and
a scientific steering committee to review proposed trials to
determine the scientific merits and prioritize trials for acti-
vation and implementation. To foster impartial peer review
of proposed trials, members of this steering committee
would be excluded from authoring papers resulting fro m
a p p roved trials. Each participating center would be elec-
t ronically linked to maximize intragroup communication
and facilitate the conduct of the trials initiated. It was also
proposed that the IBMTR/ABMTR and the NMDP would
provide core facilities for data management and analysis, as
well as on-site reviews to ensure accuracy of data and their
i n t e r p retation. It was anticipated that such a cooperative
group would provide a unique mechanism for rapid accrual
of patients and efficient and accurate conduct of defin i t i v e
phase III trials of transplantation strategies. Also anticipated
was that the group and its participating centers would be
able to derive support for these clinical trials from both NCI
and NHLBI as well as from pharmaceutical companies
interested in conducting trials of new biologicals, drugs, and
devices, and in testing their applications in hematopoietic
stem cell transplantation. 
The Transplantation Trials Group, as proposed, pos-
sesses several of the characteristics recommended by Dr. R.
Wittes for a network of this kind. Furthermore, as noted by
Dr. M. Horowitz, the inclusion of the IBMTR/ABMTR and
NMDP as centers for data collection and analysis would also
p e rmit comparative assessments of the results of diff e re n t
trials, both with the historical results compiled by the
IBMTR/ABMTR and NMDP and with the ongoing results
of transplantations being conducted by institutions not par-
ticipating in the trials of the group. The NMDP has also
developed effective methods for ascertaining data quality
and protocol compliance through its participation in ongo-
ing trials sponsored by the NHLBI. Alternative group struc-
tures might also serve as mechanisms for developing, organ-
izing, implementing, and validating phase III studies. Other
data management groups, such as those associated with
existing cooperative groups, could be re c ruited to pro v i d e
this function.
Several concerns were raised by participants at the Key-
stone and NIH meetings re g a rding the organization and
function of the transplantation trials group as pro p o s e d .
Principal among these were concerns re g a rding the place of
the transplantation trials group within the overall national
p rogram of cooperative groups developed for clinical trials
re s e a rch. The cooperative groups sponsored by the NCI,
for example, have each conducted phase III trials compar-
ing allogeneic or autologous marrow transplantations with
other modes of therapy in the treatment of diff e rent malig-
nancies. These trials are clearly disease-oriented and are
not focused on transplantation-related issues. Furt h e rm o re ,
the conduct of several of the randomized trials and the
length of time that has been re q u i red to develop and imple-
ment each trial have been so protracted that the re s u l t s
achieved have very often been obsolete by the time of their
p u b l i c a t i o n .
N e v e rtheless, with considerable re s t ructuring of existing
cooperative groups, it could be argued that an effective mech-
anism for the conduct of several disease-focused clinical trials
a l ready exists and that the establishment of a transplantation
trials group would serve only to further dilute this national
e ff o rt. For this reason, re p resentatives of the Childre n ’s Can-
cer Study Group (Dr. Jean Sanders) and the Southwest
Oncology Group (Drs. F. Appelbaum and K. Blume) re c o m-
mended that the phase III trials, which would be conducted
by a multicenter transplantation trials group, be coord i n a t e d
with existing cooperative groups so that these 2 c o o p e r a t i v e
g roup strategies would be mutually complementary rather
Table 3. New Initiatives in the Treatment of Transplant Complications*
Treatment and Prevention of Transplantation Complications Potentiation of Immune Complications Reconstitution
Tumor-targeted therapies Adoptive cell therapies
Host-specific cytoreduction Restoration of thymic function
Pharmacokinetics-based Cytokines (eg, IL-7)
Genetics-based Growth factors (eg, IGF-1, GH)
Prevention or modulation of VOD Thymic epithelial grafts
Improved antiviral agents Dendritic cell or immediate precursor grafts
Adoptive cell immunotherapies of viral diseases
*GH indicates growth hormone; IGF-1, insulin-like growth factor-1; and VOD, veno-occlusive disease.
Table 4. Opportunities in the Genetics of Marrow Transplantation*
Comparative assessments of HLA microvariant disparities as 
alloantigen targets and obstacles to genetically restricted 
interactions
Natural killer–cell receptor systems in allorecognition and tumor
resistance
Genetic polymorphisms affecting drug metabolism, normal and
malignant tissue sensitivity, and their potential for repair
HLA typing by chip technologies
Computerized design of drugs and biologicals modulating tumor and
alloantigen recognition and effector function (peptidomimetics,
CD4, CD8 analogues)
Disease-associated genetic mutations as determinants of therapeutic
outcome
*HLA indicates human leukocyte antigen.
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than competitive. They also recommended that the transplan-
tation committee chairs from the diff e rent cooperative gro u p s
be included in the planning and establishment of any newly
f o rmed transplantation trials cooperative group. 
A further recommendation was that the trials con-
ducted by any transplantation trials group be confined to
studies of transplantation-related problems, such as new
a p p roaches to the treatment of graft-versus-host disease
(GVHD); the characterization and exploitation of the
graft-versus-leukemia (GVL) effect; or the development of
new strategies to improve immunologic reconstitution or
reduce transplant-related complications. A concern was
also raised that because many of the hematologists/oncolo-
gists re f e rring patients for transplantation are alre a d y
members of existing cooperative groups, failure to engage
these hematologists/oncologists, and the cooperative
g roups to which they belong, and the activities of any
transplantation trials group would likely cripple such a
g roup before it began.
A second concern focused on the mechanisms where b y
trials would be prioritized for conduct by a transplantation
trials group. In the absence of a better- d e fined discipline for
selection and prioritization of trials, the transplant trials
g roup, as proposed, could evolve into nothing more than
another cooperative group in which trials are selected too
often on the basis of compromise and the biases of stro n g
personalities. It was recommended that the selection of trials
for conduct be based on scientific merit, that the trials be
c o n fined to studies that could be answered with accruals of
no more than 100 to 150 patients, and that the scientific
review and selection of trials be conducted by individuals
who would not play a major role in the trial design or con-
duct, and specifically would not be included as authors. Some
f u rther suggested that data management and analysis be con-
s i d e red as a contract and service rather than as criteria for
a u t h o r s h i p .
It was also recommended that such a transplantation tri-
als group be reviewed by an external scientific advisory
group, principally composed of oncologists not engaged in
transplantation, and experts in transplantation, including
some persons from the European cooperative groups who
are not members or participants in a US trial group’s activi-
ties. It was further recommended that an independent Data
and Safety Monitoring Board be established to monitor tri-
als and patient records at participating institutions.
A third concern focused on the mechanisms where b y
the NCI and NHLBI would support the research activities
of such a transplantation trials group. The consensus of the
participating investigators was that the funds currently allo-
cated for support of clinical re s e a rch by single institutions
and cooperative groups were insufficient to carry out cur-
rent programs of cooperative multicenter clinical trials
re s e a rch. This assertion seemed well in accord with the
recent findings reported to Dr. R. Klausner by a committee
chaired by Dr. J. Armitage, which was charged to assess the
clinical trials infrastru c t u re in this country as a testing
a p p aratus for the development of improved methods for
d i a g n osis and treatment of cancer [1]. For this reason, the
establishment of any transplant trial cooperative eff o rt was
c o n s i d e red unfeasible unless new monies are appro p r i a t e d
for this purpose.
REASSESSMENT OF THE CURRENT NEED FOR PHASE III
TRIALS FOR VALIDATION VERSUS PHASE II TRIALS
EXPLORING INNOVATION IN HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Although several issues and concerns re g a rding the stru c-
t u re, interactions, functions, and funding of a transplantation
trials group designed to conduct phase III clinical trials in
hematopoietic stem cell transplantation were raised and dis-
cussed at Keystone, more generic concerns were raised by the
d i rectors of several large transplantation programs. These
c o n c e rns involved the relative need for phase III trials
designed to validate certain aspects of transplantation medi-
cine versus the need to develop a more cohesive and effic i e n t
a p p roach to the conduct of phase II trials that explore the
impact of diff e rent innovative approaches as adjuncts or mod-
i fications of established transplantation re g i m e n s .
The need for phase III trials for Food and Drug Admin-
istration approval and licensure of new drugs, biologicals,
and devices is clearly recognized. Several leaders of trans-
plantation centers that are actively engaged in clinical trials
voiced the need for a more rapid and efficient funded m e c h a n-
ism to test the many innovations suggested by the results of
p reclinical and phase I clinical trials for their impact on
transplantation results when introduced into the complex
regimens used for autologous and allogeneic hematopoietic
stem cell grafts. However, when these leaders were asked to
Table 5. A National Program for Clinical Trials Research in 
Hematopoietic Cell Transplantation Under NCI-NHLBI Joint Sponsorship*
Competing Grants for Consortia of Committed Institutions to
Conduct Phase II Studies of Novel Agents and Strategies
1. Biologicals for graft-versus-host disease prevention
2. Novel strategies for stem cell selection or tumor cell purging for
autografts
3. Disease-targeted biologicals (eg, radioconjugates)
4. Biologicals for promotion of immune reconstitution
5. Novel nonmyeloablative conditioning regimens
6. Adoptive cell therapies with allospecific or tumor-selective
T/natural killer cells
7. Alternative allogeneic donor grafts and the genetic features
affecting outcome
8. New applications of allotransplants (eg, autoimmune diseases,
solid tumors)
Establishment of a Transplantation Trials Group for Conduct of 
Critical Phase III Trials Stringently Selected on the Basis of Results
of Phase II Trials from Consortia and Single Centers
Establishment of a Network of Facilities to Provide Critical Biologicals
for Conducting Clinical Trials at Collaborating Institutions
1. Monoclonal antibody production and standardization
2. Generation of immune cells for adoptive cell therapy
3. Supply of critical immunomodulatory or myelomodulatory 
biologicals or their antagonists
4. Reference laboratories for analysis of molecular polymorphisms of
major and minor alloantigens and genes affecting drug and 
radiation sensitivity and repair
*NCI indicates National Cancer Institute; NHLBI, the National Heart,
Lung, and Blood Institute.
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identify transplantation-related issues in need of phase III
validating trials, the number of trials suggested was e x t re m e l y
limited. A general concern is that current single-center- b a s e d
a p p roaches to the conduct of phase II trials and to the testing
of new transplantation approaches, or new agents as adjuncts
to standard approaches, cannot advance the field of clinical
hematopoietic stem cell transplantation at even a fraction of
the pace of new developments presented by advances in
molecular pharm a c o l o g y, tumor immunology, immuno-
genetics, and molecular cell biology. Because new agents and
new approaches are evolving so rapidly, there is a need for
new clinical trial infrastru c t u res permitting rapid patient
a c c rual and for new phase II designs incorporating targ e t e d
end points and permitting the rapid identification of the
most promising new agents and new strategies.
F u rt h e rm o re, new, more disciplined approaches to the
selection of regimens to be tested in phase III trials must be
developed so that only exceptionally promising approaches are
tested against the current best standard regimens. This would
be with the expectation, based on results of phase II trials, that
the significance of the improvement achieved through the
i n t roduction of the new test strategy can be established in a
trial requiring the accrual of no more than 200 patients.
NEW DEVELOPMENTS WARRANTING PHASE I/II CLINICAL
TRIALS AND THEIR IMPLICATIONS FOR THE FUTURE
The challenges and opportunities presented by the
extraordinary pace of advances made in transplantation biol-
ogy and related fields are illustrated in Tables 1 to 4, which
present a partial list of promising new strategies that could
significantly improve transplantation outcomes. These new
strategies affect every stage of transplantation, from selec-
tion of donor and cytoreductive regimens to the approaches
available to enhance engraftment, prevent or treat GVHD,
eradicate residual host-derived malignant cells, and treat or
prevent infectious complications in the post-transplantation
period. The potential impact of several of these initiatives
on the future of hematopoietic stem cell transplantation is
p rofound and could fundamentally alter approaches to the
t reatment of many malignant and nonmalignant diseases.
The following section provides a brief description of some
of the possibilities presented by these developments.
Until recently, allogeneic marrow grafts could be safely
applied only to those with suitably matched sibling donors.
Such transplantations still constitute most of the allogeneic
hematopoietic cell transplantations perf o rmed. However,
allogeneic marrow grafts are now broadly applicable as a
Figure 1. A 3-tiered national program for transplant trials research.
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result of international pools of human leukocyte antigen
(HLA)–typed donors for unrelated marrow allografts [2],
e m e rging pools of HLA-typed unrelated cord blood grafts
[3], and demonstrations in limited phase II trials conducted
initially in patients with severe combined immunodeficiency
[4,5] and more recently in patients with leukemia [6,7]. The
result is that T-cell–depleted HLA haplotype–disparate
donors can also be effectively used to achieve full hemato-
poietic reconstitution without the risk of severe or lethal
GVHD. Furthermore, advances in the molecular genetics of
histocompatibility now permit more refined definition of
HLA class I– and II–matched unrelated donors [8,9].
Indeed, studies by single centers and small cooperative
g roups in this country, Europe, and Japan are now in
p ro g ress to determine which microvariants of HLA class I
or II alleles constitute critical targets for graft re j e c t i o n ,
GVHD, GVL reactions, or impaired reconstitution of
HLA-restricted antigen-specific T-cell responses [10,11]. In
addition, minor allogeneic systems that may contribute to
graft failures, GVHD, or enhanced leukemia resistance are
now being identified and molecularly characterized [12,13].
It took almost 2 decades for investigators to venture
beyond the standard myeloablative pre p a r a t o ry cytore d u c-
tive regimen of single-dose total-body radiation and
cyclophosphamide. However, we have seen the introduction
of leukemia-ablative chemotherapeutic preparative regimens
[14] and less toxic and more effective hyperf r a c t i o n a t e d
radiation protocols [15,16], as well as the more re c e n t
recognition that high doses of T cells and hematopoietic
stem cells may permit the establishment of an allograft after
p reparation of the host with nonmyeloablative re g i m e n s
[17,18]. These developments have radically altered possibili-
ties for the development of safe and tolerable conditioning
regimens that are effective in eradicating disease and provid-
ing adequate immunosuppression to permit durable engraft-
ment of an allogeneic hematopoietic cell graft. In addition,
the recent introduction of tumor- t a rgeted therapies using
radioconjugated monoclonal antibodies [19,20], tumor-
selective T cells and natural killer cells, or genetically con-
trolled alloreactive populations [21-24] may replace broadly
cytotoxic preparative regimens with more focused assaults
on malignant populations. The result will be reduced risks
of transplant complications and enhanced effectiveness.
A major focus of research in transplantation biology has
been the definition of cellular interactions that contribute to
graft failures and GVHD. Advances in this area have led to
n e w, more effective immunosuppressive drug regimens for
the prevention or modulation of GVHD in HLA-matched
recipients [25], and to highly effective methods for depleting
a l l o reactive T-cell populations from the marrow graft.
These advances have radically reduced the risk of GVHD in
both HLA-matched and HLA-disparate hosts [4,6,7,26,27].
The most promising of these approaches is the application
of new biologicals, such as monoclonal antibodies, lectins,
and receptor ligands, for depletion of host-reactive T cells
[4,6,7,26,27]. In addition, new strategies for the tre a t m e n t
of unmodified marrow grafts with analogues of critical cos-
t i m u l a t o ry molecules such as CTLB-4 Ig, or CD4 have
been developed that can inhibit broad or specific activation
of alloreactive T cells and lead to the development of host-
specific anergy or tolerance [28,29].
The early studies of Kolb et al. [30], confirmed by many
investigators [31,32], have demonstrated the potential of
adoptively transferred donor-derived lymphocytes in the
t reatment of relapses of chronic myelogenous leukemia after
transplantation. This approach has also been effective in a
p ro p o rtion of patients with acute myelogenous leukemia or
multiple myeloma, who relapse after allogeneic marro w
transplantations. The impact of this approach has been strik-
ing. Over 80% of patients with chronic myelogenous
leukemia who suffer relapse after an allogeneic marro w
transplantation can now be induced into durable re m i s s i o n s
after infusions of as few as 3 to 10 million T cells/kg derived
f rom the original donor [33]. Clinical trials are now in
p ro g ress in which donor-derived T cells selectively expanded
ex vivo, in response to unmodified host leukemic popula-
tions, are being used to induce remissions of disease [34,35].
Selective expression of certain minor alloantigens on specific
leukemias has now been identified [36], and strategies incor-
porating leukemic cell targets modified to enhance their
a n t i g e n - p resenting activity are now being readied for clinical
investigation [37]. The potential for a controlled GVHD
using minor alloantigen-specific T cells genetically modifie d
to express drug sensitivity or “suicide” genes is also being
e x p l o red, in clinical trials [23].
These clinical investigations have also spawned a host of
studies designed to define the effector cells contributing to
the adoptively transferred tumor resistance and to develop
novel approaches for generating and isolating T cells specific
against minor alloantigens or fusion gene peptides expre s s e d
by the host leukemia to enhance resistance in the post-trans-
plantation period [21,38]. Similar strategies are also being
e x p l o red in which autologous T cells are sensitized to tumor
peptides presented by cultured dendritic cells and expanded
for use in conjunction with autologous marrow grafts to
enhance tumor resistance [39,40]. In addition, several new
strategies have been developed which may permit re t a rg e t i n g
of effector cells by genetically engineering these effector cells
to express tumor- s p e c i fic receptor molecules [41]. Cumula-
t i v e l y, these studies have produced a renaissance in tumor
i m m u n o l o g y, the seeds of which derive from clinical rather
than laboratory investigations.
Advances have also been made in our understanding of
the pathogenesis of several transplant-associated complica-
tions, such as veno-occlusive disease of the liver and herpes
v i rus–associated infections.  These have led to better
approaches for predicting patients at risk and for initial lim-
ited explorations of prophylactic measures to prevent such
complications [42]. Novel therapies using ex vivo expanded
virus-specific T cells have also been developed. Preliminary
studies suggest that these therapies can be highly effective in
the prevention or treatment of Epstein-Barr virus lym-
phomas and cytomegalovirus infections in the post-trans-
plantation period [43-45].
Because the applications of marrow grafts have expanded
to include most persons with leukemias and lymphomas,
p a rticularly patients over the age of 50, the diff e rences in
the kinetics and quality of immune reconstitution achieved
by young (younger than 21 years old) versus older transplant
recipients and between recipients of HLA-matched related
versus unrelated or HLA-disparate related grafts have
become glaringly apparent [46,47]. The expression of these
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d i ff e rences has been a heightened and prolonged risk of
lethal infections in the post-transplantation period. Increas-
ing evidence implicates dysfunctions of the host thymic
e n v i ronment resulting from age-associated atro p h y, GVH
e ffects on the thymus, or ineffective T-cell maturation
resulting from genetic disparities between donor and host in
the pathogenesis of impaired immune reconstitution [47].
P romising strategies invoking growth factors such as
insulin-like growth factor (IGF)-1 and interleukin (IL)-7
and transplantation of thymic epithelial cells or stromal cell
p rogenitors to foster T-cell reconstitution are now being
prepared for clinical evaluation.
Given the broad array of highly promising appro a c h e s ,
which can be invoked to foster the effectiveness of a trans-
plantation and extend its application to a broader pro p o rt i o n
of patients in need of such a potentially curative therapy, it
is clear that more expeditious and efficient clinical trial
strategies must be developed if more than a small perc e n t-
age of these strategies is to be effectively tested in phase II
studies as adjuvants to or alternatives for current transplan-
tation regimens. Those few transplantation centers larg e
enough to conduct phase II trials of their own discoveries
can be expected to continue to do so with funding thro u g h
competitive PO1, RO1, or R23 grant mechanisms. How-
e v e r, even large, established centers are encountering diffi-
culties accruing the number of patients re q u i red for such
trials owing to the proliferation of transplantation pro-
grams at smaller regional centers. Most important, several
p a rticularly promising innovations, such as the CD4 ana-
logues developed at Thomas Jefferson University Medical
Center [28], the autologous transplantation program for
autoimmune disorders at Nort h w e s t e rn University [48],
and the studies of genetically modified viru s - s p e c i fic T- c e l l
lines for adoptive immunotherapy of Epstein-Barr viru s
lymphomas have small, targeted patient populations. Ade-
quate patient accrual for a promising phase II trial at any
single center can take many years to realize [43,44].
LIMITED ACCESS TO BIOLOGICALS AND ITS IMPACT
ON THE PROGRESS OF HEMATOPOIETIC CELL
TRANSPLANTATION
A review of the new opportunities presented in Tables 1 to
4 illustrates another pressing need of the transplantation com-
munity: access to promising new biologicals exhibiting stro n g
potential in therapeutics. Indeed, the majority of the most
p romising new therapeutic strategies involve the application of
biologicals, such as monoclonal antibodies, cytokines, re c e p t o r
ligands and their antagonists, or synthetic analogues, and
p a t i e n t - s p e c i fic agents such as ex vivo expanded fusion gene
peptide-specific, tumor idiotype-specific, or viru s - s p e c i f i c
T cells, peptide-pulsed or vector- m o d i fied dendritic cells, or
idiotype vaccines. Many of these agents have been discovere d
or developed by investigators engaged in transplantation-
related re s e a rch. However, the clinical application of these
agents has been inhibited by lack of access to good manufac-
turing practice (GMP) facilities for production and quality
c o n t rol testing at a scale sufficient to permit phase II or phase
III trials. This problem is compounded by the fact that the
market for such products is considered so limited that biotech-
nology companies are often dissuaded from partnering in the
development of these therapeutic modalities. For the same re a-
son, agents (eg, IL-7 and IGF-1) initially generated by
biotechnology and pharmaceutical companies often cannot be
accessed by the transplantation community for evaluation. In
addition, these companies are wary of testing their new agents
as adjuncts to a type of therapy associated with high risks of
comorbidities and mort a l i t y.
To address this pressing problem, an alternative source
for such reagents, sponsored by the NIH, must be devel-
oped. Possibilities include a central facility or a coordinated
network of contracted facilities, either of which can produce
these promising biologicals under conditions and in quanti-
ties required for clinical trials.
A PROPOSAL FOR A COORDINATED NATIONAL INITIATIVE
TO EXPEDITE EVALUATION OF NEW AGENTS AND
TREATMENT STRATEGIES AND TO FOSTER RAPID
INCREMENTAL ADVANCEMENT OF THE CURATIVE
POTENTIAL OF HEMATOPOIETIC CELL
TRANSPLANTATIONS
Given the progress already made in the field of clinical
hematopoietic cell transplantation; the challenges presented
by recent advances in transplantation-related laboratory and
clinical research; and the limitations and inadequacies of the
current clinical trials infrastructure to conduct or sustain a
program of phase II trials adequate to evaluate, in a timely
manner, the growing list of experimental therapeutic oppor-
tunities, a new coordinated national initiative is not only jus-
tifiable, but is likely to yield substantive results for the
investment made. This initiative should at least be jointly
sponsored and reviewed by the NCI and NHLBI and devel-
oped through competitively reviewed proposals from inves-
tigators in clinical hematopoietic stem cell transplantation
research and related fields.
The national program proposed encompasses 3 major
components, which are listed in Table 5 and presented as
the initiative network envisioned in Figure 1.
I n t e r a c t i v e Consortia for the Development and
Conduct of Inno v a t i v e Phase I/II and Advanced
Phase II T r i a l s
The first component of the national program would
entail the establishment of 4 to 6 consortia, selected by
competitive peer re v i e w, each composed of a limited num-
ber of transplantation centers and joined by common sci-
entific goals or common access to critical facilities or
reagents. These consortia would conduct promising phase
I/II and advanced phase II trials of new strategies devel-
oped by 1 or more investigators or institutions. The con-
s o rtia would be selected on the basis of the quality of the
clinical trials proposed and the capacity of the consort i u m
to achieve rapid patient accrual and penetrating analyses of
populations under study, with the expectation that each
p roposed trial would be completed within 1 to 3 years. It is
expected that these consortia would allow strategies
e m e rging from small centers to be tested expeditiously,
t h e reby complementing phase II trials being conducted at
l a rge centers that are funded through PO1 or other mech-
anisms. The consortia could also include large centers
when the objectives of the trial are focused on less com-
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mon diseases such as aplastic anemia or on transplant-
related problems such as veno-occlusive disease.
Each consortium would have a lead institution and prin-
cipal investigator responsible for the administration and con-
duct of the clinical trials. Trials would be selected or devel-
oped by a steering committee composed of the principal
investigators from each center. The overall organization of
each consortium could be similar to that of the disease-
s p e c i fic clinical centers funded by the NHLBI. Such consor-
tia could be composed of geographically widely separated
centers sharing common scientific interests and objectives in
an area of transplantation medicine, or of regional consort i a
c e n t e red around an institution with GMP or good laboratory
practice facilities capable of producing or providing critical
reagents such as radioconjugates, specially manipulated mar-
row grafts, or specialized cells for adoptive cell therapy
essential to the trials being conducted by the consort i u m .
This limited network of consortia, established to effic i e n t l y
conduct promising phase I/II trials and phase II trials, should
be interactive and sufficiently flexible to permit, when practi-
cable, inclusion of centers from other consortia that are
i n t e rested in participating in specific phase II trials, pro v i d e d
that such trials do not interf e re with trials being conducted
by the center’s primary consortial affil i a t i o n .
The consortia would be established to conduct phase I/II
and phase II trials of innovative strategies and the adjunctive
use of novel agents that are designed to address critical bio-
logic issues and clinical problems that limit the applications
or success of hematopoietic stem cell transplantation as a
curative therapeutic approach for malignant disorders and
lethal acquired or genetic disorders of hematopoiesis and
i m m u n i t y. Clearly, the list of new options to be tested is long.
F u rt h e rm o re, the history of clinical hematology and oncol-
ogy suggests that substantive therapeutic advances have
often evolved from stepwise improvements in a basic tre a t-
ment strategy, or from the way a new agent is used in the
context of a complex regimen such as a transplantation.
For this reason, I propose that each phase II trial to be
conducted should be designed with targeted goals and end
points, such that a single-arm trial of the new agent or
strategy would be expected to yield the anticipated re s u l t
after accrual and analysis of no more than 25 to 50 p a t i e n t s .
The targeted goal should be set prospectively at a high
level so that the targeted result, if achieved, could be
demonstrated to be a significant improvement over those
achievable by current standard approaches in a confirm a-
t o ry trial requiring no more than 100 to 200 patients. This
a p p roach to phase II trial design clearly runs the risk of not
identifying an approach or agent capable of modestly
i m p roving current results. However, such a strategy does
p e rmit invocation of early stopping rules at any time in the
a c c rual of patients if the trial results fall short of the tar-
geted goal. This, in turn, allows investigators in a consor-
tium to be able to rapidly test, in a sequence of small trials,
modifications of an approach designed ultimately to
achieve the result targeted, or, if the approach is not
p romising, to test other strategies.
If the phase II trials were so designed, re q u i red patient
a c c ruals could usually be realized within 1 to 2 years. For
such trials, each consortium could use the biostatistics and
data management systems already established at a member
institution, or could contract with the national data center
described in the following section for the phase III trials
g roup, or, to avoid re d u n d a n c y, with one of the existing
clinical trials gro u p .
A National Network of Facilities for Production of
Critical-Grade Biolo g i c a l s
The second component of the initiative would be a net-
work of facilities funded and contracted by the NCI and
NHLBI and coordinated through a central committee com-
posed of re p resentatives from the NCI and NHLBI, the
facility heads and the principal investigators of the consort i a ,
and the phase III trials group (vide infra), which would be
c h a rged with the development of critical biologicals in quali-
ties and quantities sufficient for initial phase I/II trials,
advanced phase II trials as adjuncts to transplantation re g i-
men, and phase III trials (if warranted). This network could
be centered within a national production facility, such as that
developed at Frederick, Maryland, which could produce cer-
tain of the reagents, such as novel monoclonal antibodies,
fusion gene peptides for vaccines, or cytokines. The central
facility could also act as a conduit for reagents produced by
p h a rmaceutical or biotechnological firms, much as the Can-
cer Therapy Evaluat ions Program has provided new
a n t i n e oplastic agents for such trials. However, such a central
facility would need to be complemented by a network of up
to 6 separate, potentially regional facilities to produce the
types of patient-specific reagents that are critical to many of
the most promising new strategies sush as the generation of
tumor or viru s - s p e c i fic T-cell lines or cones, idiotype vac-
cines, and cultured and vector- m o d i fied dendritic cells. The
latter specialized products would ideally be produced by, and
under the supervision of, investigators who have pioneere d
their development and clinical application. Principal investi-
gators or directors of such programs would compete for con-
tracts to fund the establishment and functions of appro p r i a t e
GMP facilities needed for the production of such patient-
s p e c i fic cells for clinical trials. Such a facility could also be
associated with a specific consortium to provide cellular
reagents essential to its trials and scientific objectives.
The NIH has already established, through competitive
contract funding, networks of GMP facilities for pro d u c-
tion of vectors and transduced cell populations for gene
t h e r a p y. It has also established cord blood transplant banks.
Thus, the precedents for such facilities and their coord i n a-
tion are already in place.
A National Cooperative Group for the Conduct of
Phase III Trials of New Transplantation Strategies
The third component of the national initiative would be
a multicenter cooperative group for the conduct of phase III
trials testing new transplantation-related strategies and new
applications of hematopoietic stem cell grafts, particularly in
the treatment of nonmalignant diseases.
The organization of this clinical trials group could
include most of the features of that proposed by the Trans-
plantation Trials Group, but would also include cert a i n
modifications of the proposed plan. The purpose of these
modifications would be to foster coordination of the overall
national effort; to provide guidelines to be applied a priori
to the selection and prioritization of trials to be conducted
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so that only the most promising trials, requiring limited
a c c rual to achieve a substantive result, are implemented;
and to ensure that the activities of this group complement
rather than compete with the activities of already establ i s h e d
disease-focused cooperative groups.
The Transplant Trials Group would be open to all
transplantation centers accredited by the Foundation for the
A c c redidation of Hematopietic Cell Tr a n s p l a n t a t i o n
(FAHCT), the National Bone Marrow Pool, or by coopera-
tive groups that commit to the conduct of proposed clinical
trials and to the accrual of all potentially eligible and con-
senting required for the completion of these trials.
This group would be governed by a steering committee
composed of members re p resenting 7 groups: (1) a group of 5
to 6 members elected from re p resentatives proposed by each
p a rticipating transplant center, (2) the principal investigator
or designated re p resentative from each transplantation con-
s o rtium, (3) 1 to 2 members selected from the directors of the
s u p p o rting biologicals production network, (4) 3 m e mb e r s
selected from the chairs of the transplantation committees of
the national cooperative groups, (5) 2 members re p re s e n t i n g
the NCI and the NHLBI, (6) 1 member from the gro u p ’s
P rotocol Review Committee, and (7) 1 member from the
g ro u p ’s data coordinating center. The steering committee
would be charged with governing the group; identifying and
planning trials for consideration by the group; implementing
prioritized protocols approved by the Protocol Review Com-
mittee; defining reagent, patient and data support re q u i re-
ments for studies planned; and establishing and org a n i z i n g
e ffective communications. These communications would be
between member institutions; between the group and the
c o n s o rtia and single centers conducting phase II trials;
between the group and the facilities producing essential bio-
logicals; and between the group and the NHLBI and NCI.
The group would have an independent Pro t o c o l
Review Committee. This committee would consist of a
small group of established clinical investigators in the fie l d s
of hematology, oncology, and transplantation together with
an equal number of leading biostatisticians expert in
advanced clinical trial designs. The committee would be
responsible for reviewing the scientific merit, statistical
p rojections, and feasibility of each protocol proposed for
clinical trial. It would develop guidelines for assessing pro-
posals for phase III trials, including criteria that must be
met by the results of phase II trials when compared with
relevant historical data, to justify selection for a phase III
validation study. Since the accumulated literature in mar-
row transplantation has rarely included trials with more
than 100 to 150 patients accrued to an experimental trans-
plantation arm, only trials that can provide definitive re s u l t s
with accruals of that magnitude over a period of 1 to 3 y e a r s
should be considered acceptable. The Protocol Review
Committee would then review each proposed phase III trial
using these criteria, select those trials meeting such pre d e-
t e rmined criteria, and recommend a prioritized list of trials
for implementation to the steering committee.
The group would require a Data Coordinating Center.
The Transplantationation Trials Group has proposed con-
tracting the IBMTR/ABMTR and NMDP for this function.
These are large and well-established national resources that
could provide this function. Each has developed sophisti-
cated, computerized data-capturing systems. Because most
transplantation centers in the United States already re p o rt
to 1 or both of these databases, it would be cost-efficient to
recruit their expertise. However, certain of the cooperative
g roups also have sophisticated data centers, skilled in the
accession and management of data from phase III trials that
might compete effectively with the statistical operation of
IBMTR/ABMTR for this activity.
As suggested by several investigators at the April meet-
ing, this Trials Group should also have an independent
Data and Safety Monitoring Board established to re v i e w
patient re c o rds and data submitted from each part i c i p a t i n g
c e n t e r. Both the NHLBI and the NCI have established
mechanisms for the appointment and function of such inde-
pendent monitoring board s .
The Transplantation Trials Group should also establish
an External Scientific Advisory Board to review its activities
and plans for clinical research in the field of hematopoietic
cell transplantation. This board should include leaders in
experimental and clinical transplantation research from the
fields of oncology, hematology, immunology, pharmacology,
and genetics, who are outside the clinical transplantation
c o m m u n i t y, as well as independent experts in transplanta-
tion, including leaders from Europe.
CONCLUSION
This re p o rt presents a useful summary of issues to be
a d d ressed in planning a national agenda to exploit the
advances being made in hematopoietic cell transplantation
and related biomedical disciplines. I have tried to include
in this summary most of the concerns and possibilities
voiced by the many investigators who attended the meet-
ings in Keystone and at the NIH. The Tr a n s p l a n t a t i o n
Trials Group proposed at Keystone and the 3-tiered pro-
gram proposed in this summary are each models that are
hoped to provide a framework for future discussions
between the NCI and NHLBI and the clinical investiga-
tors engaged in re s e a rch in hematopoietic cell transplanta-
tion as the institutes plan for the future. The potential for
p ro g ress at this time is exceptional. A reassessment of the
i n f r a s t ru c t u re and mechanisms of support for the conduct
of clinical trials re s e a rch in this field is indicated. A care-
fully considered national initiative at this time could
g reatly accelerate the pace of advances in this import a n t ,
scientifically rich field of investigation.
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